Phase 3Completed
Comparison of Compliance and Evolution of Functional Capacity of Patients With Rheumatoid Arthritis Treated by Methotrexate Either by Auto-injector or by Conventional Sub-cutaneous Syringe (Self-i)
A National, Randomized, Open-label Study Comparing Compliance and Evolution of Functional Capacity of Patients With Rheumatoid Arthritis Treated With Methotrexate Administered by Auto-injector Versus Administration by Conventional Subcutaneous Injection.
- Sponsor
- Nordic Pharma SAS (Industry)
- Enrolment
- 278 enrolled
- Conditions
- Arthritis, Rheumatoid
- Interventions
- Methotrexate
- Ages
- adults, older adults
- Registry
- NCT02553018
Full record on ClinicalTrials.gov
From the registry
The primary objective of the study is to compare, in patients treated with methotrexate injection for rheumatoid arthritis, the compliance and the health assessment questionnaire evolution for the administration by auto-injector versus administration by conventional subcutaneous injection, after 6 months of treatment.
Primary outcomes
- Co-primary criteria: observance and health assessment questionnaire
History
Last registry update
Primary completion
Registered
Started